1. Scrip
  2. >>Therapy Areas

Vertex’s Type 1 Diabetes Cell Therapy Gets A Boost – And Some Competition

Sernova One Step Ahead On Implantable Device

 
• By Andrew McConaghie

Vertex has invested heavily in advancing its stem-cell based candidates for type 1 diabetes, but Sernova has inched ahead in the race to bring a functional cure for the condition to patients.

Vertex HQ, Boston

Hopes of freeing type 1 diabetes patients from daily insulin injections or insulin pumps are growing, with Vertex and rival Sernova making progress on their cell therapy-based candidates.

Vertex first revealed promising early data from its allogeneic stem cell-derived cell therapy, VX-880, nearly two years ago showing that injected insulin-producing islet cells drastically cut the first patient’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.